Find Clinical Drug Pipeline Developments & Deals for Taurolidine

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Taurolidine,Citric Acid,Heparin Sodium

            Therapeutic Area: Infections and Infectious Diseases Product Name: Defencath

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 31, 2020

            Details:

            U.S. FDA has accepted for filing the Company’s submitted New Drug Application (NDA) for Defencath™, its product candidate to be used as a catheter lock solution in hemodialysis patients for the prevention of catheter related blood stream infections (CRBSI).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Taurolidine,Citric Acid,Heparin Sodium

            Therapeutic Area: Infections and Infectious Diseases Product Name: Defencath

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: SunTrust Robinson Humphrey

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Public Offering July 27, 2020

            Details:

            The Company plans to use the net proceeds for general corporate purposes, including obtaining regulatory approval and commercialization of Defencath™ in the U.S., research and development, and working capital and capital expenditures.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Taurolidine,Citric Acid,Heparin Sodium

            Therapeutic Area: Infections and Infectious Diseases Product Name: Defencath

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 08, 2020

            Details:

            Defencath is being developed as a catheter lock solution with an initial indication for use of preventing catheter-related bloodstream infections (CRBSIs) in patients with end-stage renal disease who are receiving hemodialysis via a central venous catheter.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Taurolidine

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: New Jersey Economic Development Authority

            Deal Size: $6.0 million Upfront Cash: $5.2 million

            Deal Type: Funding February 03, 2020

            Details:

            The funding will help CORMEDIX make preparations for an anticipated commercial launch of Neutrolin® in the U.S. market. The company is planning for a approval of a new drug application for Neutrolin.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Taurolidine

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 03, 2020

            Details:

            Neutrolin has received Fast Track Designation from FDA and the company confirmed with FDA in a pre-NDA meeting that it was eligible to request a rolling review.